The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Diagnostics firms Quanterix Corp. and OncoGenesis teamed up to develop a quantitative, protein biomarker test for cervical health that OncoGenesis will market in developing countries.

The partners will develop the CerMark test using Quanterix’ next-gen Simoa planar technology, which measures up to 10-plex biomarkers to detect acute and baseline disease levels at much smaller amounts than are possible using traditional ELISA assays. The test will be developed on Quanterix’ SP-X benchtop imaging and analysis system and will allow for the quantification of high-risk HPV infection and cervical health biomarkers. Once CerMark is approved and launched in developing countries, women will use OncoGenesis’ iPap home collection kit to collect cervical specimens and send them to a lab, which will perform the CerMark analysis.


+ Show All | – Hide All

Financials

There are no financials available.

Product Information


Click a keyword for comparable deals.

Product 1 of 4
Product Type Diagnostic
Brand Name CerMark
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Reproductive System Cancer
Cervical Cancer
Infectious & Viral Diseases
STDs
HPV
Licenser Name Quanterix Corp.
Clinical Developer OncoGenesis
Quanterix Corp.
Licensee Name OncoGenesis

Product 2 of 4
Product Type Diagnostic
Brand Name iPap
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Reproductive System Cancer
Cervical Cancer

Product 3 of 4
Product Type Diagnostic
Brand Name SP-X

Product 4 of 4
Product Type Technology
Brand Name Simoa